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Radiation dermatitis is a common side effect of external beam radiation therapy. The
purpose of this study was to evaluate the effectiveness of applying an aloe vera based skin
gel to the target area skin in preventing the development of radiation dermatitis to postlumpectomy/mastectomy patients receiving external beam radiation therapy in an ambulatory
radiation-oncology clinic in the southeastern region of the United States. In this descriptive
correlational study, a convenience sample of willing participants (n=18) was followed from
initial treatment through the one-month follow-up examination to assess the intensity of their
skin reaction.
Five research questions were examined pertaining to the relationship
between prognostic indicators and the development of radiation dermatitis when Radiacare®
gel was used before and throughout external beam radiation therapy post-mastectomy or
post-lumpectomy. The prognostic indicators used in this study were: Breast size > C-cup,
prior chemotherapeutic exposure, length of incision, age of client, and weight changes since
diagnosis. Analysis of Variance (ANOVA) and Pearson's Correlation Coefficients were
used in the data analysis with a confidence of p=0.05. This study indicated that breast size
and weight changes were the most prognostic of the factors studied.
The small sample size and lack of randomization or control group limit the generalizability of
these findings to clinical practice; however, it does support the need for continued research in
this area. Recommendations for future studies include comparing Body Mass Index (BMI) to
incidence and determining a relationship between gel use and treatment breaks and if there is
a difference in the length of time until the skin is restored to baseline upon completion of
therapy.
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PREVENTION OF RADIATION-INDUCED SKIN REACTIONS
IN BREAST CANCER EXTERNAL IRRADIATION
Chapter I
Significance
Radiation dermatitis is a common and sometimes debilitating side effect experienced
by post-lumpectomy/mastectomy clients receiving external beam radiation therapy.
Many factors have been identified as contributing to the development of radiation
dermatitis including breast tissue greater than C-cup, size of lumpectomy/mastectomy
scar, use of radiosensitive medications (including chemotherapeutic agents), age and poor
nutritional status. Knowledge of these factors can be used by healthcare professionals to
predict which patients could benefit from aggressive prevention of this complication.
Nurses assist women to deal with the devastating emotional, spiritual and physical
effects that encompass the diagnosis and treatment of breast cancer. Since there are
many changes with which the client will have to cope, the prevention of problems
associated with the treatment of this disease becomes of primary importance to both the
client and nurse. Many women are choosing breast conserving surgery and adjunctive
irradiation of the remaining breast tissue as their treatment option when faced with the
diagnosis of breast cancer (Kolcaba and Fox, 1999). Other women are choosing to
receive chest wall irradiation following mastectomy. It is known that as many as 95
percent of patients receiving external beam radiation therapy will experience radiation
induced skin changes known as radiation dermatitis (Porock, Nikoletti & Kristjanson,
1999). Some skin reactions are mildly irritating, while others may require interruption of
treatment schedule (Williams et. al., 1996). Some reactions are so severe that ulceration,
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infection and/or necrosis of tissue will occur (Archambeau, Penzer & Wasserman, 1995).
Since cosmesis is often a factor when selecting lumpectomy and radiation, prevention of
severe side effects are important because these complications could lead to permanent
scarring and loss of affected tissue (Archambeau et. al., 1995). Archambeau and
colleagues (1995) also noted that the development of the most severe chronic skin
reactions were seen in those clients who developed the more severe acute skin reactions.
Hoskins (1997) also noted that women who did not develop side effects from treatment
reported less psychological distress and a greater perceived health status than those who
did. It is also known that the psychological attitude of the clients and their perceived
health status can greatly affect the outcome of the treatment. Since nursing is charged
with assisting the clients to deal with and prevent problems associated with their
treatment process, and external beam irradiation is known to cause irritating or
debilitating skin reactions, identification of an agent that could prevent those skin
reactions without adverse reactions is desirable.
Purpose Statement
The purpose of this study was to evaluate the effectiveness of applying an aloe vera
based skin gel to the target area skin in preventing the development of radiation
dermatitis to post-I umpectomy/mastectomy clients receiving external beam radiation
therapy in an ambulatory radiation/oncology clinic located in the southeastern region of
the United States.

Research Questions
1.

What is the relationship between breast size and the incidence of radiation
dermatitis when using Radiacare® gel before and throughout external beam
radiation therapy?

2.

What is the relationship between the prior use of radiosensitive agents and the
incidence of radiation dermatitis when using Radiacare® gel before and
throughout external beam radiation therapy?

3.

What is the relationship between the length of the surgical incision and the
incidence of radiation dermatitis when using Radiacare® gel before and
throughout external beam radiation therapy?

4.

What is the relationship between the age of the client and the incidence of
radiation dermatitis when using Radiacare® gel before and throughout external
beam radiation therapy?

5.

What is the relationship between weight changes since diagnosis and the
incidence of radiation dermatitis when using Radiacare® gel before and
throughout external beam radiation therapy?

Definitions
Breast Size
Breast is a term used to describe paired mammary glands located on the anterior
surface of the thoracic cage. Varying amounts of subcutaneous and retromammary
adipose tissue provide a vast range in the individual's breast size and shape. Breast size
is identified as a numerical and letter value placed upon the measurement of the tissue
and comparing the differences in measurement.
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The numerical value is recorded in inches and is obtained by measuring the
circumference of the chest wall immediately inferior to the axillary fold and rounded to
the nearest even whole number. The letter value is obtained by measuring around the
fullest point of the bust line and recording this measurement in inches. The difference
between the two numbers is calculated and a letter value is recorded based upon a the
following scale:
1"
2"
3"

A
B
C

4"
5"
6"

D
DD
DDD (F)

Large breast size was classified as a measurement greater than C-cup size in the affected
breast post operatively.
Radiosensitive Agents
Radiosensitivity is the term used to identify any pharmacological or chemotherapeutic
agent that intensifies the effect of radiation especially upon the skin. A list of all current
prescription and nonprescription medications including herbal supplements and vitamins
was obtained from each participant. Those medications were reviewed for known
radiosensitivity. A history was taken to record current or previous exposure to
radiosensitizing chemotherapeutic agents; the dosage and the time lapse since last
chemotherapeutic treatment was recorded.
Surgical Scar
Scar tissue develops when there is an interruption of skin integrity. Repair of this
breech in normal skin tissue is accomplished by the formation of densely packed granular
tissue commonly referred to as a scar. The length and location of each participant's
surgical scar was obtained and recorded in centimeters. The location was identified by
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the quadrants of upper lateral (including tail of Spence), upper medial, lower lateral and
lower medial as well as mixed lateral, medial, superior, inferior or mastectomy
(Appendix 1). Clients with edema, erythema, or an open, draining wound in the
treatment area at the onset of therapy were excluded from the study.
Age
Age is a term that reflects the cumulative existence of a person since birth. For this
study, each participant's age was recorded in years by subtracting the numerical
representation of the year in which the study was conducted from the numerical
representation of the year in which the participant was born.
Weight changes
The measured relationship between a mass of a body and the effect of gravity is
conceptualized by the term weight. In this study, the participant was questioned as to
their weight immediately before the diagnosis of cancer. Weights were measured on the
day of the initial consultation, weekly throughout the treatment regimen, and again at the
four-week follow-up appointment. Weights were recorded in pounds and rounded to the
nearest one-tenth.
Radiacare® Gel
Aloe is identified as any number of plants within the lily family from which the sap of
the spiky leaves can be applied topically to skin insults, including burns, for its
therapeutic properties. Acemannan hydrogel, an extract of Aloe vera L., is the active
ingredient in Radiacare® Gel, which is developed and marketed by Carrington
Laboratories, Inc. It has been approved for prescription use by the Food and Drug
Administration for the management of skin conditions associated with first and second
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degree burns, stasis and decubutis ulcers, and superficial skin conditions including
radiation dermatitis (Plemons, et. al., 1994). Acemannan has been shown to affect direct
interaction of monocytes and macrophages that is believed to directly affect actions in
such a manner that epithelialization and collagen deposits are hastened thus improving
wound healing (McDade, Lutz and Fosmire, 1995).
Application
Application is defined as the spreading of a thin layer of a substance to the hand and
transferring that substance topically to another area to disperse the substance evenly in
order to receive the desired benefit from that substance.
Radiacare ® Gel 1.5 ounce sample tubes were given to the clients during the initial
consultation and simulation visit with a prescription for a four ounce tube with five
refills. The clients were instructed to apply the gel to the skin within the treatment
markings two to three times daily from the date of initial consultation continuously
through the four-week post-radiation follow-up appointment (Appendix 1).
External Beam Radiation Therapy
Standard External Beam Radiation (EBR) Therapy is exposure of a defined area to a
concentration of X-rays with the desired purpose of interrupting the growth of neoplastic
cells within that area. External Beam Radiation Therapy for post-lumpectomy or
mastectomy is delivered each weekday in 200 cGy fractions over a period of twenty-five
(25) consecutive treatments for a total radiation dose of 5000 cGy. An additional Boost
of 1200 cGy is directed at the site of the lump for a total dose of6200 cGy.

7
Radiation Dermatitis
Radiation dermatitis is a global term for any adverse skin changes that can be directly
attributed to external beam radiation therapy. These changes range from erythemia or
bronzing of the skin within the treatment area to ulceration, infection and necrosis. This
reaction may be so severe as to interrupt therapy. Many measurement scales have been
suggested and tested for the accurate assessment of these skin reactions. For this study, a
six-point descriptive scale was be utilized. This scale, adopted by the Oncology Nursing
Society (Bruner, et.al, 1998), attempts to standardize the subjective description of
radiation induced skin reactions.
Scale:
Grade

I

faint or dull erythema, follicular reaction

Grade

II

bright erythema

Grade

III

dry desquamation with or without erythema

Grade

IV

small to moderate amount of wet desquamation

Grade

V

confluent moist desquamation; edema

Grade

VI

Ulceration, hemorrhage, or necrosis

Development of a Grade V reaction subjects the client to an interruption in therapy.
Since radiotherapeutic effects are cumulative, the goal is to avoid disruptions in the
treatment plan (Archambeau, Pezner & Wasserman, 1995). There are no published
reliability or validity statistics available on this scale.
Incidence
The incidence of radiation dermatitis was calculated by the summation of the total
skin reaction scores in each site (incision area, inframammary fold, axilla (where
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appropriate) and overall treatment field) throughout the treatment plan.
Conceptual map
The numbers of known and suspect factors contributing to the development of
radiation dermatitis are beyond the scope of this study and were limited to five. For the
questions concerning the relationship these five factors have on the incidence of radiation
dermatitis when using Radiacare® gel before and throughout external beam radiation
therapy, a conceptual map was drawn as follows:
It is known that EBR + these listed factors = Radiation Dermatitis.

External
Beam
Radiation

+
+
+
+
+

Large Breast Size
Radiosensitive Agents
Surgical Scar Size
+ Radiacare ® Gel
Age
Weight Changes

?

Radiation
Dermatitis

Contributing Factors not addressed in this study
Fair skin complexions
Immunocompromisation
Prolonged Radiation Exposure
Smoking or History of Skin Cancer
Non-adherence to recommended skin care
Postmenopausal state
Co-morbidity of HPT, CVHD, or
Autoimmune diseases
Summary
No topical agent has been shown to prevent radiation-induced skin reactions in those
receiving external beam radiation therapy. Since research indicates that 95 % of these
clients will develop some type of skin reaction, it is imperative that a method of
preventing this complication be found. Prior studies have focused upon the treatment of
such skin reactions; however, few have examined methods of prevention. Both nurses
and clients are interested in preventing potentially debilitating complications and
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therefore improving the outcomes of the treatment plan. A review of the relevant
literature was conducted to identify both contributing factors to the incidence of radiation
dermatitis and agents recommended for prophylactic use.

Chapter II
Review of Literature
In professional literature, the effects of radiation on the skin and breast tissue are
described. Several studies (Appendix A-2) have been published addressing prognostic
indicators for severe skin reactions to irradiation. Much has been written about the use of
topical agents to treat moderate radiation-induced skin reactions while others address the
most effective treatment plans and dressings for the more severe manifestations;
however, very few studies have been published that specifically address the prophylaxis
of radiation-induced dermatitis despite the acknowledgement of possible severe longterm effects with the development of acute skin reactions.
Effects of Radiation on the Skin and Breast Tissue
Radiation has been known to cause skin changes since 1901 when Henri Becquerel
first developed ulceration while transporting radium in his pocket (Sitton, 1992a).
Clients may be familiar with the skin changes seen with ultraviolet blue radiation (UVB)
commonly called "sunburn"; however, the radiation used with external beam radiation
therapy is quite different from other types of ionizing radiation (Noble-Adams, 1999).
The rapid abi lity of the normal skin cells to repair themselves from ionizing radiation and
the inability of the malignant cells to do so is the advantage of radiation therapy (NobleAdams, 1999; Archembeau, Penzer & Wasserman, 1995). The reaction of the skin
ranges from mild erythema to ulceration and necrosis of tissue.
Prognostic Indicators for Severe Skin Reactions
Clinicians assumed that the same skin type risks to UVB radiation would also predict
those most at risk for developing radiation-induced dermatitis; however, studies have
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failed to support this assumption (Lokkevik et. al, 1996; Williams et al, 1996; Maiche,
Isokangas & Grohn, 1994; Sitton, 1992). Review of professional literature finds that the
type of radiation employed, the length of exposure time, the strength of dose and the size
and location of the treatment field are the most accurate prognostic indicator for
development of severe skin changes. It was indicated that the longer the exposure time,
the stronger the dose, or the larger the treatment field, the greater the risk of severe skin
reaction (Porock, Nickoletti & Kristjanson, 1999; Noble-Adams, 1999; Archembeau et.
al., 1995; Sitton, 1992).
An additional factor known to increase risk of severe skin reaction for women
receiving post-lumpectomy or post-mastectomy irradiation was the concurrent use of
radiosensitive chemotherapeutic agents (Noble-Adams, 1999; Porok et. al, 1998;
Turesson et. al., 1996). Other significant prognostic factors for the development of
severe skin reaction to radiation therapy were identified by Porock and colleagues (1998)
as smoking, irradiation of appositional skin folds (axillary and inframammaiy), weight or
large breast size, previous lymph aspiration or resection, wearing tightly fitting clothing,
and skin-to-skin friction in the treatment field. Other studies have identified age
(Turesson, et. al, 19%), poor nutritional status (Sitton, 1992) nonadherence to
recommended skin care (Noble-Adams, 1999; Porock, Nicoletti & Kristjanson; 1999;
Sitton, 1992), menopausal state (Porock etal, 1998; Turesson et. al., 1996; Sitton, 1992)
and that which is identified in the literature as "patient-to-patient variability" (NobleAdams, 1999; Porock et.al., 1998; Turesson et. al., 1996; Sitton, 1992). It is this
unknown factor, patient-to-patient variability, that requires prophylactic treatment be
given to all clients receiving irradiation to the breast or chest wall. Co-morbid existence
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of disease such as hypertension, cardiovascular disorders, history of skin cancer, and the
presence of autoimmune diseases are also included as contributory factors (Turesson et.
al., 1996).
Use of Topical Agents to Treat Radiation-Induced Skin Reactions
Much has been written about therapeutic agents used in the treatment of radiationinduced skin reactions, although there is little empirical evidence to support their
effectiveness. Mild erythema and dry desquamation have been treated with topical
ointments including wax, paraffin, olive oil, and almond & chamomile creams with
discouraging results (Maiche, Grohn, Maki-Hokkovien, 1991). Weak, topical
corticosteroids such as 1% hydrocortisone and 0.05% clobetasone cream have been used
but are known to mask signs of infection in inflamed skin (Sitton, 1992). Gleese,
Mameghan-Zaheh and Sparkes (1979) saw such a severe skin reaction with the use of the
0.05% clobetasone cream that they recommended discontinuance of the use of topical
steroids until the causative factor could be identified. Kolcaba & Fox (1999) and Hogan
(1997) have also published the results of works with guided imagery to manage the
symptoms of pain, burning, and itching that are associated with the skin reactions. When
moist desquamation develops, tradition dictated cleansing the area with half-strength
peroxide and saline then applying 1% gentian violet solution (Porok, Nicoletti &
Kristanjanson, 1999); however, current evidence discourages the use of peroxide on an
open, draining wound. Both the use of hydrocolloid (Margolin et al, 1990) and moisture
vapor permeable dressings (Porock, Nickoletti & Kristjanson, 1999) have been used on
open draining wounds to heal and prevent infection with promising results.
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Hydrocortisone versus Clobetasone cream
Gleese, Mameghan-Zaheh and Sparkes (1979) studied the use of 1% hydrocortisone
cream or 0.05% clobetasone cream in a double blind randomized study of 54 clients
receiving external beam radiation therapy for breast cancer. Once the client's radiation
dosage had reached 2000 rad, they were given one of the creams and instructed to apply a
thin layer two or three times a day even if no skin reaction was seen. The reaction of the
clobetasone group's skin was so much worse than the group receiving hydrocortisone that
the researchers did not recommend the use of either cream until the reason for such a
reaction could be identified. Modern improvements in the delivery of radiotherapy of the
radiation beam and narrowing of the irradiation field may encourage a replication study
of these medications. Application of the creams at the initial treatment visit may also
improve the outcome as research has identified the early part of the second week of
treatment as the most frequently seen in the development of erythema (Noble-Adams,
1999; Archambeau, Pezner & Wasserman, 1995; Sitton, 1992).
Sucralfate Cream
The use of sucralfate cream was studied on fifty breast cancer clients receiving
external beam radiation post-mastectomy or lumpectomy. (Maiche, Isokangas & Groh,
1994). A double-blind study was utilized with each client acting as her own control. A
thin layer of either sucralfate cream or a placebo cream was applied to either side of the
scar beginning with the initial radiation treatment (up to third treatment). The skin was
evaluated weekly on a five-point scale for degree of skin reaction by either the physician
or oncology clinic nurse. Sucralfate was selected based on its success with mucosal
membranes and the hope that the sucralfate would enhance growth of epithelial cells
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(Maiche et. al., 1994). Their study found that grade I (erythematic) and grade II (dark
erythema/pain) developed much later on the sucralfate treated side, that healing occurred
much faster and there was a less likely chance of the development of later skin reactions.
The findings of this study were encouraging. A larger sample group and replication of
the use of this medication in other settings would be helpful in validating the findings.
Dexpanthenol cream
Lokkevik and colleagues (1996) studied the effects of dexpanthenol cream for its
prophylactic properties with clients undergoing either breast or laryngeal irradiation. The
active ingredient in dexpanthenol, panothothenic acid, is known to decrease the effects of
dermatitis and was selected to promote epithelial formation and regeneration thus
preventing severe radiation-induced skin reactions. Sixty-three breast cancer clients were
included in the eighty-six total subjects studied. Twenty-one of those sixty-three were
receiving concurrent low-dose chemotherapy. This study also used a subjective fivepoint scoring system (0 = no reaction, 1 = mild reaction, 2 = moderate reaction, 3 =
severe reaction, 4 = moist desquamation). Clients were ineligible to participate if they
had a history of prior skin disease, allergy to the studied agent, were unable to cooperate
with the study or had their radiation therapy postponed for any reason. This study found
no clinically significant difference in skin reactions with the use of this cream, and it was
removed from their clinic's routine skin care protocol.
Biafine ® burn cream
Szumacher (2000) reported on a study describing the results of phase two of a clinical
trial in sixty patients from the Toronto area who were given the burn cream marketed as
Biafine ® upon initiation of their external beam radiation treatments post mastectomy or
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lumpectomy. The study used the Oncology Nursing Society scale for recording skin
reactions. Although eighty-three percent of the clients still developed grade II radiation
dermatitis, only six percent developed grade III and no one developed the most severe
forms, grade IV and V. She indicated that while these results did not find a prophylactic
benefit for the use of the cream, it did suggest that its use could benefit the client by
limiting the severity of the skin reaction allowing the clients to continue their treatment
plan uninterrupted and thus receive the benefits of the full cumulative effect of the
radiation therapy.
Fisher and colleagues (2000) reported the results of a randomized study of 172 women
receiving radiation therapy post-mastectomy/lumpectomy comparing the use of Biafine ®
burn cream with the participating clinic's choice of best supportive care product or notreatment. Best supportive care product choices included Aquaphor ® (31%) and Aloe
Vera (34%). Sixteen percent of the participants had no treatment to the treatment field
(Fisher et al, 2000). While this study did not support the superiority of the use of Biafine
® over the comparative products, it did suggest that the use of this cream hastened the
healing of the skin reactions in women with large breasts and in the nonsmoking (Fisher
et al, 2000).
Aloe Vera
A study was found that evaluated the effects of aloe vera gel as a prophylactic agent in
ameliorating radiation dermatitis. One hundred ninety-four clients were double blind
randomized into groups to receive a 98% pure aloe vera gel or an inert gel (used as the
base of the aloe vera gel). Both the clients and healthcare providers rated the irradiated
skin field on a weekly basis with a four-point scale being used. This study found no
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statistical evidence to support the use of aloe vera gel; however, some of the healthcare
providers questioned the historical decrease of radiation dermatitis during the twelvemonth study period. A second study was then used with one hundred eight clients
randomly selected to either apply the aloe vera gel or not. The same rating scale for
clients and healthcare providers was used with no clinically significant difference seen in
the development or severity of radiation-induced skin changes (Williams et al. 1996).
Acemannan
Acemannan-containing wound gel dressings were applied to the irradiated skin fields
of mice by Roberts and Travis (1995). They found that mice that were treated before the
onset of skin erythema were much less likely to develop adverse skin reactions than those
whose treatment was delayed until the onset of symptoms. They found the application of
the gel was most effective when it was applied immediately after the irradiation of the
skin. If application was delayed until manifestation of symptoms occurred, the gel did not
prevent the progression of the dermatitis; however, those who continued to apply the gel
healed at a faster rate than those groups who used no gel, personal lubricating jelly (KY), or Aquaphor ® a prescription healing ointment. It was also noted that application of
the gel to mice in the other groups after severe acute dermatitis had developed did not
improve healing time.
Summary
The effects of radiation on the skin and breast tissue are known and described in the
professional literature (Appendix A-2). Prognostic indicators for severe skin reactions to
irradiation have been researched with encouraging results. While much has been written
about the treatment of radiation-induced skin reactions, little has been done to discover an
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agent that could prevent the development of these reactions despite the potentially
detrimental effects of radiation-induced skin reactions on the client's skin, interruption of
treatment and the severe long-term effects associated with the development of acute skin
reactions including infection, necrosis and loss of healthy breast tissue.

Chapter III
Methods
In this chapter, the methods and design for the study will be described. The design,
instruments, setting and sampling, data collection, ethical considerations involved and
data analysis will be explained. Limitation of the study's internal and external validity
and attempts to control these factors will also be addressed.
Design
In this descriptive study, clients were instructed to apply Radiacare ® gel to the
radiation treatment area at least two to three times daily from the initial consultation until
four weeks after the completion of treatment. Skin reactions within the treatment area
were assessed weekly and scored based upon the Oncology Nursing Society's skin
reaction scale (Bruner et al, 1998). Skin reactions were analyzed and compared to the
known high risk factors of large breast size, increased length of surgical incision and
recent chemotherapeutic exposure as well as suggestive factors of age and weight
changes. It is known that application of this gel is effective in the treatment of radiation
treatment induced skin reactions; this study was to determine if application from the start
of radiation treatment may prevent the occurrence of radiation-induced skin reactions
(Plenums, et. al, 1994).
Instruments
A data assessment form (Appendix 1) was used to document the skin assessment for
participants throughout their treatment plan. Information about the suggestive factors of
breast size, exposure to chemotherapeutic agents, length of incision, age and weight was
recorded as well as a weekly assessment of the treatment skin area including the entire
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breast, axillary and inframammaiy skin folds, and the surgical incision areas. The skin
reaction was scored according to the Oncology Nursing Society's skin assessment scale.
The client's age, weight changes, and skin complexion type, bra size and previous
exposure to chemotherapeutic agents were recorded for comparison purposes.
Breast Size
Since the inframammary skin fold has been identified as a high-risk area for radiation
induced skin reactions in women with larger breasts, clients receiving post-lumpectomy
irradiation will be asked to identify their post-operative brassiere cup size. Large breast
size was identified as C-cup size or larger.
Radiosensitizing Agents
A list of the client's current medication regimen was obtained, and each drug will be
assessed for its degree of radiosensitivity. In addition, a history was taken to determine if
known radiosensitizing chemotherapeutic agents such as dactimomycin, doxorubicin,
methotrexate, 5-flurouracil, and/or hydroxyurea were used (Bruner et. al, 1998). The
time lapse since chemotherapeutic exposure was recorded.
Incision Length
The length and location of each participant's surgical scar was obtained and recorded
in centimeters. The location was identified by the quadrants of upper lateral (including
tail of Spence), upper medial, lower lateral, and lower medial as well as mixed superior,
inferior, lateral or medial. Clients with edema, erythema, or an open, draining wound in
the treatment area at the onset of therapy were excluded from the study.
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Age
Age has been identified in previous studies as a contributing factor in the decreased
healing time for radiation dermatitis and other skin integrity problems. It was included in
this study to explore the relationship between age and the development of radiationinduced skin reactions when Radiacare® gel is applied according to the study's protocol.
Weight Changes
Studies have linked poor nutritional status to both loss of skin integrity and delayed
wound healing. A comparison of baseline body weight and weekly weights was
included. It is acknowledged that the assumption of good nutritional status before
diagnosis is idealistic.
Skin Complexion Type
Although radiation-induced skin reactions affect the basal layer of skin, anecdotal
data suggest that fairer complexions are more likely to experience the more severe skin
reactions. This comparison was made by having the skin complexion type assigned by
the client's self-report based upon the following scale:
Fair:

burns easily with minimal sun exposure

Medium:

burns with sun exposure but rarely blisters

Dark:

rarely burns with sun exposure

Radiation Dose
Each client's cumulative weekly radiation dosage was recorded. Differences in
treatment length and area were compared. Breaks in consecutive treatments were also
recorded with a rationale for its need.
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Skin Assessment
In 1994, the Oncology Nursing Society adopted a six-point skin assessment scale for
radiation-induced skin reactions (Bruner et. al, 1998). The scale allows for
standardization and improved communication between practitioners. Documentation of
skin reactions were identified as
0 = No changes noted
1 = Faint or dull erythema, follicular reaction
2 = Bright erythema
3 = Dry desquamation with or without erythema
4 = Small to moderate amount of wet desquamation
5 = Confluent moist desquamation; edema
6 = Ulceration, hemorrhage, or necrosis
For this study, the entire treatment area, axillary skin fold, inframammary fold, and
area adjacent to the surgical incision were assessed. Any skin reaction was graded and its
location noted on the data collection form.
Setting and Sampling
The participants of this study were selected from an outpatient radiation oncology
clinic in the southeastern United States. All clients who were referred for postlumpectomy or post-mastectomy irradiation were asked to participate. Those who had a
known sensitivity to aloe vera, were unable or unwilling to comply with the application
of the gel, had edema, erythema or an open wound to the treatment area were excluded
from the study.
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Intervention
Each participant was given a skin care protocol (Appendix 3) that included the
application of the Radiacare ® gel. Sample tubes of the gel were provided along with a
prescription for additional tubes. Each week, the client was asked about application of
the gel and the clinic nurse, using the above-mentioned Oncology Nursing Society scale,
assessed the skin for reactions.
Data Collection
Upon signed consent to participate (Appendix 4), the client was asked to identify her
age, weight change since diagnosis, skin complexion type, post-operative bra size and
exposure to chemotherapeutic agents. The clinic nurse recorded medications, herbal
supplements and vitamins in use, measured and identified the location of the surgical scar
and assessed the treatment area skin. A data collection sheet (Appendix 1) was placed in
the chart. Each week, the client was asked to confirm continued use of the gel. The nurse
assessed the treatment area skin and recorded the assessment of the breast fields, weight,
medication changes and cumulative radiation dose. After the four-week follow-up
appointment, the form was removed from the chart and the data was transferred to a tally
sheet from which comparison to that of other participant's data was made. At the
conclusion of the study, each participant's data was tabulated and reported. A
comparison of skin reactions each week and between each risk factor was examined
Comparisons were made as to the influence the application of the gel may have had on
the participant's skin. All results are given in grouped data to decrease the chance of
individual identification of a participant.
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Ethical Considerations
This study included human participants and was reviewed by the university's Human
Subjects Review Board (Appendix 5) as well as the Medical Center's Research Review
Committee (Appendix 6). The treatment under study has been the standard treatment
protocol within this population for the clinic since February 2000 and was conducted to
evaluate its clinical validity (Appendix 7).
Participants were solicited from the clients referred to the clinic for post-mastectomy
or post-lumpectomy irradiation. Each client had the study explained to them by the
researcher and was asked to provide a written consent to participate (Appendix 4). The
participants were given a copy of the consent, which included the procedure for
withdrawal from the study. Care was taken to stress that participating in the study would
merely allow the data collected to be used for research purposes and would not change
the skin care recommendations they received. After the participant's one-month followup appointment was completed, her data assessment form was removed from the chart to
ensure anonymity of the data.
Data Analysis
The data analysis for this descriptive study included frequencies and the measures of
central tendency including mean, median and mode. Comparisons between each
suggestive factor and the degree of skin reaction were analyzed using Analysis of
Variance (ANOVA). Client's use of the gel and the skin's reaction were also compared.
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Study Limitations
Internal Validity
In this study, internal validity may be questioned since the selection of participants
was based upon those who were referred to the clinic for irradiation during the study
timeframe, those who consented to participate and those who were willing or able to
continue to participate throughout the study. The lack of a control group and
randomization in selection limit the ability to identify with confidence the use of the
Radiacare ® gel as the influencing factor in the incidence of the development of radiation
dermatitis.
Sample Size
Study participants were solicited from those clients (all women) who were referred for
irradiation post-mastectomy or post-1 umpectomy during the study timeframe. There was
no reliable mechanism for predicting the number of referrals that would be made within
that period.
Attrition
As in any study, a certain amount of attrition is expected. There are those participants
who may wish to withdraw, those from the sampling pool who are not eligible to
participate, and those who do not complete the treatment plan. This attrition factor will
decrease the already limited sample size and will have a negative effect on the
generalizability of any relationships identified.
Subjectivity of Skin Reaction Analysis
The use of the Oncology Nursing Society's skin assessment scale, while helpful, does
not eliminate the subjectivity of the skin reaction scores. To minimize this effect, the
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number of persons who assessed the scores was limited to the two researchers who are
Registered Nurses, employed by the clinic and are familiar with the study and its purpose.
Further validation was provided by the medical director's independent assessment of the
skin condition.
External Validity
The external validity of this study is threatened since random selection of participants
was not used. This approach prevents generalization to the population of all clients
receiving external beam radiation therapy post-lumpectomy or mastectomy. Multiple
treatment interference may also threaten the external validity in that it is not known what
cumulative effects of prior treatments (such as chemotherapy) or other current treatments
may have had on the development of radiation dermatitis.
Setting and Sampling
It was expected that the clients for this study would be primarily female, Caucasian
and over the age of 60, thereby limiting its generalizability to the entire population;
however, it does reflect the profile of those with breast cancer that are receiving postsurgical irradiation. This study was conducted within a mid-sized regional medical
center in the southeastern United States, which may influence the demographic reliability
of generalization to more rural or urban settings, or to those with more ethnic diversity.
Reactive Effect
While it is vital that clients be aware of and consent to participation in this study, this
requirement may not only limit the size of the sample but may also influence the
subjective data required from the participants, especially the validity of the self-reporting
of the continued use and frequency of use of the gel throughout the treatment.
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Summary
The design of this descriptive study was to maximize the available data and minimize
factors that could distort the validity of the findings. A review of the literature was
conducted to determine those factors identified as suggestive or directly implicated in the
development of radiation-induced skin reactions and were included in this study to
discover the relationship between the application of the Acemannan containing Radiacare
® gel and the prevention of the development of these skin reactions. Care was taken to
control those factors that could influence the data collection and analysis as well as limit
the generalizability of the findings to the general population. It was the purpose of this
study to determine if there is a relationship between the application of this gel and the
prevention of the development of radiation dermatitis in participants with intervening
factors such as large breast size, exposure to radiosensitive agents, healed surgical
incisions, advanced age and weight changes since diagnosis.

Chapter IV
RESULTS
Between April 1,2001 and October 31,2001, 19 eligible clients were solicited for
participation in the study. One declined and the remaining 18 were followed throughout
their treatment regimen. Demographically, 89% of the women (n=16) were of European
ancestry and 11% (n=2) were of African decent. There was no attrition. Twelve women
identified their breast cup size as cup-C or larger and the affected breast was equally
distributed between the right and left side.

Five participants were treated with

chemotherapy before the onset of their radiation. No woman in this study received
concurrent chemotherapy with the external beam radiation. The incision size ranged
from 2.5 cm to 12.5 cm with a mean of 5.9 cm. All but one of the participants was
receiving post-lumpectomy irradiation with two thirds of the incisions being located on
the lateral aspect of the affected breast. The age range of the participants was 30 - 87
with a mean age of 56.7. Five clients were aged 30 - 49; nine were between the ages of
50 - 69, and the remaining four were aged 70 - 89. Most women (n=13) claimed no
weight change from the time of initial diagnosis until the onset of radiation therapy. Of
those who did report a change, three cited a weight loss (-2, -5,-10 pounds) while two
indicated they had experienced a weight gain (+5, +10). At the conclusion of the
treatment plan, the mean weight change was a loss of 5.3 pounds. Five questions were
addressed with this study and statistical data collected and analyzed to discover the
degree to which the use of Radiacare gel might influence the development of radiation
dermatitis.
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Question One:
What is the relationship between large breast size and the incidence of radiation
dermatitis when using Radiacare® gel before and throughout external beam radiation
therapy?
Analysis of Variance indicated that there was no relationship between the incidence of
radiation dermatitis within the entire treatment field (p=0.741) between large-breasted
women and small-busted; however, there was a stastically significant difference noted
between those groups at both the area around the incision site and the inframammary skin
fold. Women with size C-cup breasts or larger were likely to have a more intense skin
reaction along the incision line (p=0.0249) or the inframammary fold (p=0.0180) than
those who were smaller busted. Since this finding has been reflected in prior studies, the
application of Radiacare® had no influence on the incidence of radiation dermatitis.
(Figure 1)
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Figure / : Comparison of incidence of radiation dermatitis between large-breasted and
small-breasted women throughout treatment field (incidence), and at the breast,
incision, inframammary skin fold, and axillary sites.
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Question Two
What is the relationship between prior exposure to chemotherapeutic agents and the
incidence of radiation dermatitis when using Radiacare® gel before and throughout
external beam radiation therapy?
No relationship was seen between the women who had prior exposure to
chemotherapeutic agents and those who did not (figure 2). Incidence was determined by
calculating the total of the skin severity reactions at each site (entire breast, incision line,
inframammary fold and axilla, where applicable) throughout the treatment period then
compared by groups (chemo and non-chemo) with no stastical difference found.
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Figure 2. Comparison of total incidence of skin reaction by entire breast, area
surrounding the incision, the inframammary skin fold and mean incidence between
those who were exposed to chemotherapeutic agents prior to irradiation and those
who were not.
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Question Three
What is the relationship between the length of incision and the incidence of radiation
induced dermatitis when using Radiacare® gel before and throughout external beam
radiation therapy?
Using the Pearson's Correlation Coefficients, the length of the scar was able to
account for less than 1% of the skin reaction of the total treatment field (R2=0.616) and
for less than 2% of the reaction seen around the incision line (R2=0.02). Of interest, a
negative correlation (r=-0.08141) was seen between the incision length and the incidence
of skin reaction at the inframammary skin fold (Figure 3). This end result could indicate
a positive relationship between the use of Radiacare ® gel and the decrease in the skin
reaction at the inframammary skin fold.
Incidence by Incision Size

60

Axilla
IMF
Incision
Breast
CO

to

CD

CO

lO

Individual reactions by site

Figure 4. Total incidence of skin reaction by site (axilla, inframammary skin fold,
area surrounding the incision, and entire breast) for each participant.
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Question Four
What is the relationship between the age of the client and the incidence of radiation
dermatitis when using Radiacare® gel before and throughout external beam radiation
therapy?

Figure 4. Incidence of skin reaction totals by age of client.

The relationship between age of the client and the incidence of radiation dermatitis
(figure 4) in this study was mixed. The data indicated a positive correlation between age
and the skin reaction incidence over the entire treatment field (r=0.01841). The data also
showed a negative correlation between incidence and the area around the incision line
(r=-0.03169) and the inframammary fold (r= -0.039331) that is, as age increased, a lower
incidence of radiation dermatitis occurred in each of these observation sites (figure 5).
The study findings indicate the possibility that a favorable relationship exists between the
use of Radiacare ® gel and the incidence of radiation dermatitis at the incision line and
inframammary fold in older women.
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Figure 5. Comparison of the incidence of skin reaction and age of the client by
contrasting reaction at the inframammary skin fold and incisional area.
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Question Five.
What is the relationship between weight changes since diagnosis and the incidence of
radiation dermatitis when Radiacare® gel before and throughout external beam
radiation therapy?
A positive relationship between the weight changes and the incidence of radiation
dermatitis was seen with the use of Radiacare ® gel (figure 6). By Pearson's Correlation
Coefficient, 14% of the skin reaction over the entire treatment field was correlated to
weight changes (r= -0.37524), 8% of the reaction seen around the incision site
(r= -0.28978) and 3.7% of the inframammary skin fold reaction (r= -0.19274). As weight
decreased, the skin was less likely to react. The suggestion is that the Radiacare® gel
may have positively affected the degree of skin reaction in this group of participants.
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Figure 6. Comparison of total skin reaction to amount of weight change since breast
cancer diagnosis by participant.
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Summary
The overall goal of this study was to determine if the use of Radiacare® gel before
and throughout treatment with external beam irradiation following a mastectomy or
lumpectomy for breast cancer would alter the expected skin reaction. A review of
literature identified factors that could be used to identify persons or areas most at risk for
intense skin reactions from the treatment. The use of Radiacare® gel did not change the
skin reaction intensity from that which was expected in women with larger than C-cup
breasts; however, results showed a positive relationship among women who had
undergone chemotherapy before radiation therapy, who were older or who had lost
weight since breast cancer diagnosis and decreased skin reaction.

Chapter V
Discussion
In this descriptive study, the effects of the application of Radiacare® gel before and
throughout external beam radiation therapy post-lumpectomy or post-mastectomy were
evaluated to determine if there was a difference in skin reactions from those described in
the literature. Many prognostic indices were suggested as factors that negatively
influenced the development of radiation dermatitis during therapy. Five risk factors were
selected from these to be used in this study and were identified as follows: breast size of
C-cup or larger, previous exposure to chemotherapeutic agents, length of surgical
incision, age, and weight change since diagnosis with breast cancer. The small sample
size and lack of a control group limit the generalizability of the findings; however, these
risk factors should be used to guide future studies since the use of the Radiacare® gel
may have positively influenced the degree to which the skin reacted during treatment.
Breast size
When assessing the skin reaction of women with C-cup or larger breasts receiving
external beam radiation therapy post-lumpectomy, there were more intense skin reactions
noted at the incision line and the inframammary skin fold than those seen with smaller
breasted women in the group. However, there was no stastically significant difference in
the overall treatment field when compared with the smaller breasted women receiving
treatment. It was expected that the larger breasted women would have significantly more
intense reactions in every assessed area (when compared with the smaller breasted
women under treatment); therefore, the possibility that Radiacare® gel positively affected
the skin in the larger breasted group can be considered. Of note, during this study, only
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one woman (size EEE) required a break in the treatment plan due to radiation dermatitis.
This factor is one that should be included in future studies of this nature, as the
cumulative benefit of irradiation has long been documented as most effective in treating
tumors and interruption in treatment may decrease the effectiveness of the irradiation.
Prior chemotherapeutic agent exposure
The prior exposure to chemotherapeutic agents was expected to increase the incidence
of skin reaction; however, in this study, there was no statistically significant difference
found when assessing the treatment field, axillary, inframammary fold, or incision areas.
While the study's design and sample size cited previously prevent generalizability, it is
possible to speculate that the use of the Radiacare® gel may have had a positive influence
on this factor. Future studies using control groups and random assignment to treatment
modalities should identify the role Radiacare® gel application plays in the decreased
incidence of radiation dermatitis.
Length of surgical incision
It was expected that those with larger surgical incisions would have greater skin
reactions due to the breech of skin integrity before the insult of irradiation. Each
participant was required to have a well-healed incision without a break in the skin to be
eligible for participation in this study. The length of surgical incision was able to account
for less than two percent of the skin's reaction in this study. It is possible that a larger,
more randomly selected population would reflect a different correlation. In this study, a
negative correlation was seen between the larger surgical incisions and skin reaction
incidence at the inframammary fold. This finding could be a serendipitous one, or, could
suggest that the Radiacare® gel applied to this area afforded some skin protection.
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Age of client
As with the increased incidence of skin reaction expected with a breech in the
integrity of the skin, it was expected that older skin would have more intense skin
reactions due to the loss of elasticity, moisture and slower recovery time from insults.
When assessing the overall treatment fields, the incidence of skin reaction did rise with
the age of the client; however, the areas of the inframammary skin fold and surgical
incision had a negative correlation suggesting that the application of the Radiacare® gel
may have had beneficial effect on these treatment areas. A larger, more comprehensive
study should investigate this phenomenon.
Weight change since diagnosis
The final prognostic factor evaluated in this study was the relationship between weight
change and the incidence of skin reactions when using Radiacare® gel before and
throughout treatment. Prior studies have indicated that poorly nourished skin is less
pliable and slower to heal than well-nourished skin and that the nutritional status of the
client before the onset of treatments will influence how well the skin is able to protect
and repair itself from the damage caused by the radiation. This study utilized a selfreport of the amount of weight change since diagnosis combined with the actual
beginning and ending weights to define weight changes. Future studies may consider the
use of other determinations of nutritional status or Body Mass Index (BMI) to estimate
this factor. In this sample few clients reported a weight change, and the mean weight
change throughout the twenty-five consecutive treatments was a loss of five pounds. The
assumption that the women were nutritionally healthy at the time of diagnosis was
unrealistically ideal. Even within the small sample size of this study, there were women
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who were grossly underweight as well as those who were morbidly obese. This ideal
weight assumption negates any correlations identified in this group.
While the scope and limitations of this study, as previously identified, limit its
usefulness, the results are encouraging in the potential of Radiacare® gel in preventing or
minimizing the incidence of radiation dermatitis in women receiving external beam
radiation therapy post-lumpectomy or post-mastectomy. This study's data analysis did
indicate that of the factors under consideration, forty percent of a women's degree of skin
reaction could be accurately predicted based upon knowing her breast cup size and the
amount of weight change she had experienced since her diagnosis. Incidentally, the data
also supported previous findings stating that fair skin complexion is not an accurate
prognostic factor for intensity of skin reactions while receiving external beam irradiation.
Suggestions for future studies
Suggestions for future studies include the use of a larger sample size with a control
group and more ethnic diversification of the population. In addition, the use of BMI or
other measure of nutritional status rather than weight change since diagnosis is
recommended. An objective means of recording a comparison of the number of and
amount of applications applied daily would assist researchers in evaluation of data.
Additionally, studies should analyze the frequency and duration of treatment breaks
caused by acute skin reactions, as well as time of healing of the skin back to baseline.
The participants in this study were primarily middle-aged Caucasian women of
middle- to upper-middle class socioeconomic status. A larger, more diverse population
may illicit significantly different results or may confirm those suggested in this study. As
noted previously, a more accurate measure of nutritional status is needed to better
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evaluate the degree to which the skin's nutritional health influences the incidence of skin
reactions during irradiation therapy.
The daily use of the gel and number of applications per day were self-reported and
were, therefore, subject to reactive effect. A study to compare the amount of gel applied
and/or the number of applications per day would be useful in guiding skin care protocols
using this product if further research indicates its usefulness in the prevention of or
decreased incidence of skin reactions.
Future studies should include an indication of the number of participants who are
required to have a break in the treatment regime due to severe skin reactions when
compared to a control group. If the use of this gel can prevent a break in treatment, then,
women who use this product would be able to gain the full benefit of the cumulative
effects of their therapy.
Summary
This descriptive study identified and evaluated five prognostic indicators of radiation
dermatitis in women receiving external beam radiation therapy post-lumpectomy or postmastectomy. While the small sample size and lack of a control group limits the
usefulness of the findings, there were indications that the use of Radiacare® gel may
have positive outcomes in preventing the occurrence radiation dermatitis or alleviating
the symptoms which promote treatment adherence and improved quality of life for the
client receiving treatment.
The nurse working within the radiation/oncology clinic may also use this study's
findings to reinforce skin care protocols with those women with large breasts.
Additionally, the oncology nurse should identify those with weight changes since breast
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cancer diagnosis because this factor has been identified as putting the individual at
significant risk of more severe skin reactions. Those women with both risk factors would
be especially encouraged to adhere to the skin care protocols.
Future studies should include these factors when comparing the use of this gel to
another or a control group with no treatment to assist in evaluating its effectiveness.
They should also include a more ethnically diverse population and a better mechanism
for identifying nutritional status. It is also recommended that the number of breaks in
treatment required due to severe skin reaction be compared.
Nurses assist women in dealing with the devastating emotional, spiritual, and physical
effects that encompass the diagnosis and treatment of breast cancer. It is imperative for a
product to be found that will prevent or alleviate the uncomfortable and sometimes
debilitating skin side effects experienced by women receiving external beam radiation
therapy for their cancer. Knowledge of the prognostic factors for more severe skin
reactions will be useful to the oncology nurse only if a product can be identified to offer
prevention or palliation of those symptoms. Nurses must encourage participation in
future studies to assist in the continued search for help for the suffering of the clients
entrusted to our care.
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Appendix A-l
Radiacare Project Form
Thank-you for agreeing to participate in this study. Please identify the following information.
Remember that once your treatment is completed, this form will be removed from your chart and
no one will be able to tell it was yours.
Personal Information:
Age:

Bra Size:

Amount of weight change since diagnosis:

Gain
Loss

Have you taken, or are you now taking, chemotherapy? Yes No
If so, how long since treatment completed?
Would you rate your skin complexion as?
Fair:
Medium:
Dark:

burns easily with minimal sun exposure
burns with sun exposure but rarely blisters
rarely burns with sun exposure

For Nurse to complete:
List of current prescription and over the counter medications:

Scale: 0 = no changes noted
4 = small to moderate wet desquamation
1 = faint or dull erythema, follicular reaction 5 = confluent moist desquamation; edema
2 = bright erythema
6 = ulceration, hemorrhage, or necrosis
3 = dry desquamation with or w/o erythema
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Appendix A-2
Literature Relevant to the use of Topical Agents to Treat Radiation Dermatitis
Source
1997
Gleese,

Agent
hydrocortisone vs.
clobetasone

Sample
54 Breast
Cancer

Design
Prophylaxis
Doubleblind, Exp.

Instrument
Weekly scale
1 -4

Results
clobetasone
skin reacted
severely to
radiation

1994
Maiche...

sucralfate cream

50 Breast
cancer

Doubleblind
Own control

Weekly 5 pt
skin rating

1996
Lokkevik...

dexpanthenol
cream
(panothothenic
acid)
Biofine ® vs.
Aquaphor®,
aloe vera, or pt
choice OTC

63 breast
cancer

Exp. Own
control

Weekly scale
0-4

Slower
developing
reaction, fester
healing
No sign diff
w/use of cream

172 1/2
Biafine®
1/6 ea
others

NE
Random
assignment
to groups

Weekly 4 point
scale

N o prophylaxis
Biafine ®
group healed
faster in highrisk

1996
Williams...

aloe vera

194 clients

Doubleblind;
randomized

No stastical
difference in
groups

1996
Williams

aloe vera

108 clients

Random
assignment

4 pt scale
weekly AND
Client selfassessment
questionnaire
Weekly 4 pt
scale

2000
Szumacher.

Biafine®

60 Br Ca
w/concurre
nt low
dose
chemo

NE

0 - 4 point
scale & pt
questionnaire
weekly

1995
Roberts...

Acemannan Gel

Laboratory
mice

Random
assignment

Skin
assessment

2000 Fisher

No diff in
development or
severity
Only 3%
developed
Grade III
None
developed
Grade IV
Best if applied
immediately
after Tx.
Reactions
healed better w/
continued use

Implications
Discouraged use
of either until
cause of reaction
to clobetasone
identified
Needs
replication for
validation—
encouraging
Removed from
clinic's protocol

Encouraging for
Biafine ®
Discouraging:
Aquaphor®,
Aloe vera, or
OTC remedies
Aloe vera not
supported in
prophylaxis

Aloe vera not
supported for
prophylaxis
Reduction in
severity seen
from expected

Encouraging for
use in humans
Not useful after
severe reaction
develops
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Rjilutum Oncology Gnitr
Skin Care Instructions for Breast Cancer Radiation Therapy
Radiation therapy works by exposing the cancerous area to high-energy x-rays. While both the diseased and
healthy cells are affected, the healthy cells possess a better ability to recover and the diseased cells are damaged or
destroyed.
There are many things you can do to help make your treatment a success!
1.

Protect the treatment areafromrubbing, pressure, or irritation.
•
•
•
•
•
•

2.

Wear loose, soft cotton, comfortable clothes. (Old ernes that can get ink cm them!)
Do not wear a bra or tight clothing that will rub the treatment area.
Do not starch your clothes.
Do not rub or scrub the treatment area. Use your hands to gently cleanse the area.
Do not use adhesive tape on the treatment area. If you must bandage the area, use paper tape and
try to apply it to an untreated part of the skin.
Try to keep your underarm from rubbing skin to skin—stand with your hand on your hip to keep
the skin from your arm from rubbing your underarm.

Protect the treatment areafromirritants such as:
•
•
•

Soaps, perfumes, heating pads, ice packs, or talcum powder.
Use only the deodorant provided by the Radiation Oncology Nurse.
Avoid shaving the underarm of the treated side. If you MUST shave, use an electric shaver and DO
NOT apply preshave lotions or hair remover products to the treatment side.

3.

Protect the treatment areafromthe sun during treatment and after the treatment is completed.
During
your treatment time, keep the area coveredfromsun exposure with light colored clothing. After
treatment, we recommend using a PABA sunscreen with at least a 15 rating as well as covering the
treated area with light colored clothing.

4.

Do not wash off the marks applied by the Radiation Therapists to outline the treatment area.

5.

Apply a thin layer of Radiacare gel to the inside of the outlined area FOUR TIMES A DAY beginning
on the day the outline marks are made. Continue to apply the gel throughout the treatment until your
one-month follow-up visit. The gel will protect the healthy cells from damage during treatment. It will
supply the healthy cells with moisture and help them heal after treatment is complete.
•
•

On treatment days, do not apply the gel within TWO hours of treatment and apply the gel as soon
as possible after your treatment to get the most benefit.
If itching or drainage develops, see die physician or nurse for the gel in a cooling or absorbent
formula.

6.

Eat a healthy, balanced diet and drink plenty of fluids.

7.

Avoid people with colds or other infections until your treatment is over.

8.

Ask questions! Write them down and bring them with you to your treatment sessions and follow-up
visits. You will see the Radiation Oncologist each week, usually on Wednesday, but please let us know
if you have questions or concerns before then.
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Appendix A-4
INFORMED CONSENT DOCUMENT
Project Title: Prevention of Radiation-Induced Dermatitis in Breast Cancer Irradiation.
Investigator: Cathy Eden Ammerman, Nursing, 615.451.2817
You are being asked to participate in a project conducted through Western
Kentucky University and Sumner Radiation Oncology. The University requires that you
give your signed agreement to participate in this project.
Mrs. Ammerman or Mrs. Rippy will explain to you in detail the purpose of the
project, the procedures to be used, and the potential benefits and possible risks of
participation. You may ask her any questions you have to help you understand the
project. A basic explanation of the project is written below. Please read this explanation
and discuss with Mrs. Ammerman or Mrs. Rippy any questions you may have.
If you then decide to participate in the project, please sign on the last page of this
form in the presence of the person who explained the project to you. You will be given a
copy of this form to keep.
1.

Nature and Purpose of the Project:
The purpose of this study is to determine if the gel marketed under the name of
Radiacare is effective in preventing the skin reactions that are sometimes seen in
women who are having radiation therapy after their mastectomy or lumpectomy.

2.

Explanation of Procedures:
You will be given a copy of the clinic's skin care guidelines including applying
the Radiacare Gel to the treatment site two or three times a day beginning today
and continuing to apply the gel to that area for one month after your treatments
have ended. Each week (usually on Wednesdays) you will be asked how many
times a day you are applying the gel and your skin will be checked for signs of
redness and swelling.

3.

Discomfort and Risks:
If using aloe vera in the past has caused you to develop hives or caused redness or
swelling to your skin or you have had a previous adverse reaction to Radiacare
Gel, you should not use this product. There is a slight chance that you may
develop redness, swelling, or hives to the treatment area if you develop an allergy
to the gel. If you do, you will be advised to stop using the gel and your
information will not be used in the study except to say one person was not able to
complete the study due to an adverse skin reaction to the gel.

4.

Benefits:
It is anticipated that the application of this gel will prevent skin damage from your
radiation treatments similar to the way sunscreens prevent skin damage from
sunburn.
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5.

Confidentiality:
A form like the one attached to this one will be placed in your chart upon which
the nurse will track your skin response each week. This form will also have your
age, bra cup-size, size of surgical scar, and list of your current mediations. This
information has been included to determine whether these factors change the
effectiveness of the gel in preventing skin reactions. No one except the persons
employed by the radiation clinic will be able to view the form. Once you have
completed your one-month post-treatment appointment, that form will be
removed from your chart, the skin reaction scores and above-mentioned
information will be placed on an anonymous form and the one in your chart will
be destroyed. No one will be able to determine your individual results once your
follow-up appointment is completed.

6.

Refusal/Withdrawal:
Refusal to participate or withdrawal from the study does not alter the skin care
guidelines for you. If you do not wish to continue your participation in the study,
you may withdraw from the study at anytime during your treatments until the time
of your one-month follow-up appointment. Once your information has been
transferred to the anonymous group form, it cannot be removed.
Withdrawal may be done in person by informing the nurse of your decision to
withdraw any day during your treatment or upon your one-month follow-up visit.
Refusal to participate in this study will have no effect on any future services you
may be entitled to from the University or the Radiation Oncology Clinic. Anyone
who agrees to participate in this study is free to withdraw from the study at any
time with no penalty.

I understand also that it is not possible to identify all potential risks in an experimental
procedure, and I believe that reasonable safeguards have been taken to minimize both the
known and potential but unknown risks. I also understand that my participation in this
study is voluntary.

Signature of Participant

Date

Witness

Date

THE DATED APPROVAL ON THIS CONSENT FORM INDICATES THAT
THIS PROJECT HAS BEEN REVIEWED AND APPROVED BY
THE WESTERN KENTUCKY UNIVERSITY HUMAN SUBJECTS REVIEW
BOARD
TELEPHONE: (270)745-4652

YOU MAY CONTACT THE HUMAN PROTECTIONS ADMINISTRATOR AT
THIS NUMBER
SHOULD YOU HAVE COMMENTS OR CONCERNS
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Appendix A-5
APPLICATION FOR APPROVAL OF INVESTIGATIONS
INVOLVING THE USE OF HUMAN SUBJECTS
Submit by the first working Monday of the month for screening prior to the HSRB
meeting. Please add additional space between items as needed to describe your
project.
1.

Principal Investigator's Name: Cathy Eden Ammerman, RN
Email Address: cathyea@home. com
Mailing Address: 811 Harden Street Gallatin, Tennessee 37066
Department: Nursing
Phone: (615)451-2817
Co-Investigator: Carol B. Rippy, RN, C
Email Address: rippyc@sumner.org
Mailing Address: 300 Steam Plant Road, Suite 150 Gallatin, Tennessee 37066
Department: Sumner Radiation/Oncology Phone: (615) 451 -6080

2.

If you are a student, provide the following information:
Faculty Sponsor: Dr. Beverelv E. Holland. Nursing Phone: (270) 745 - 3489
Faculty Mailing Address: AC 108-A 1 Big Red Way Bowling Green, KY 42101
Student Permanent Address (where you can be reached 12 months from now):
811 Harden Street Gallatin, Tennessee 37066
Is this your thesis or dissertation research?

Yes

3.

Title of project: Prevention of Radiation-Induced Dermatitis in Breast Cancer
Irradiation.

4.

Project Period:

5.

Has this project previously been considered by the HSRB?

6.

Do you or any other person responsible for the design, conduct, or reporting of
this research have an economic interest in, or act as an officer or a director of, any
outside entity whose financial interests would reasonably appear to be affected by
the research? NO

7.

Is a proposal for external support being submitted? NO

8.

You must include copies of all pertinent information such as, a copy of the
questionnaire you will be using or other survey instruments, informed consent
documents, letters of approval from cooperating institutions (e.g., schools,
hospitals or other medical facilities and/or clinics, human services agencies,
individuals such as physicians or other specialists in different fields, etc.), copy of

Start: May 1.2001

End: October 31,2001
NO
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I.
A.

external support proposals, etc. Attached: Informed consent document, Letters of
approval from Sumner Regional Medical Center, and Dr. Robert T. McClure,
Radiation/Oncology.
PROPOSED RESEARCH PROJECT
Provide a brief summary of the proposed research. Include major hypotheses and
research design.
Descriptive study of the effects of applying Acemannan (Radiacare Gel) in the
prevention of the development of radiation-induced skin reactions in women
receiving post-lumpectomy/mastectomy external beam radiation therapy at an
outpatient radiation oncology clinic.
Women will be asked to participate in the study and will be given a skin care
protocol that includes the application of Acemannan to the skin within the
treatment area. The skin will be assessed and assigned a reaction score weekly
throughout treatment and at the one month follow-up appointment.

B.

Describe the source(s) of subjects and the selection criteria. Specifically, how
will you obtain potential subjects, and how will you contact them?
All clients receiving post-lumpectomy/mastectomy irradiation at Sumner
Radiation/Oncology between May 1,2001 and October 31,2001 will be asked to
participate. The clients will be solicited for participation at the time of initial
consultation and simulation at which time the nurse will review the skin care
protocol and explain the study.

C.

Informed consent: Describe the consent process and attach all consent documents.
A written consent which explains the study and skin care protocol will be given to
each prospective client. Emphasis will be placed upon the fact that participation
does not alter the plan of care. See Appendix.

D.

Procedures: Provide a step-by-step description of each procedure, including the
frequency, duration, and location of each procedure.
1. Clients will be identified from new client referral list by nurse and request for
participation consent will be placed in chart with usual educational materials.
Once the clients have been deemed appropriate candidates for the ERBT, their
participation in the study will be solicited.
2. Clients who consent to EBRT will then be advised of skin care protocol
including the application of Acemannan {Radiacare Gel) and will be solicited
to participate in the data collection study. Care will be taken to emphasize
that the treatment plan will not be altered by their participation or their
decision not to participate.
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3.

D.

E.

Clients will be given sample tubes of the gel and a prescription for the gel
by the medical director with instructions to apply a thin layer to the
treatment area two to three times daily beginning with the initial
consultation and continuing until the four-week follow-up visit.
Procedures (cont.)
4.
Skin within the treatment area will be assessed on a weekly basis and
again at the four week post-treatment follow up appointment and assigned
a score based upon a six-point scale from 0 (no reaction) to 6 (necrosis).
5.
In addition data regarding, age, weight, bra cup size, size of surgical scar,
skin complexion, and a list of current medication (including
chemotherapy) will be collected to compare skin reaction severity within
sub-groups. Each of these factors has been implicated in influencing skin
reactions to EBRT.
How will confidentiality of the data be maintained? (Note: Data must be securely
kept for a minimum of three years on campus.)
Information will be collected on a form that will include the client's initials
during treatment and follow-up and kept in the client's treatment record. Once
the follow-up visit is completed, the form's data will be transferred to a central
tabulation form and the individual's form will be destroyed. Only healthcare
personnel with legal
access to the chart and the investigator will have access to the form during
treatment.

F.

Describe all known and anticipated risks to the subject including side effects,
risks of placebo, risks of normal treatment delay, etc.
Acemannan has no known side effects. It has been FDA approved in the healing
of radiation induced skin reactions. Since there is no approved prophylactic
treatment for radiation induced skin reactions, the standard treatment is to treat
the skin symptomatically.

G.

Describe the anticipated benefits to subjects, and the importance of the knowledge
that may reasonably be expected to result.
Acemannan has been shown to significantly reduce the radiation skin reactions in
laboratory mice. It is anticipated that similar benefits will be obtained in human
subjects. Acemannan is thought to support the monocytes and phyagocytic
action to improve the skin's ability to repair itself from the damages of
irradiation. The hydrogel properties of the gel are also thought to support
retention of moisture within the skin (Roberts and Travis, 1995).

n

SIGNATURES

I certify that to the best of my knowledge the information presented herein is an
accurate reflection of the proposed research project.

Principe Investigator

Date

Co-Investigator

Date

" U

Approval by faculty sponsor (required for all students):
I affirm the accuracy of this application, I accept the responsibility for the conduct of
this research, the supervision of human subjects, and maintenance of informed consent
documentation as required by the HSRB.

Date

Approval by Department Head (required for all applications)
I confirm the accuracy of the information stated in this application. I am familiar with,
and approve of the procedures that involve human subjects.
—
Department Head

i Date

- Ql

Advising Physician*:
I certify that I am a duly licensed physician in the State of Tennessee and that, acting
as advising physician; I accept the pKfcgdures prescribed herein.
,

rMlfrm.

Physician's Name and Signature

t>A*/,

Date

/

*Physician signature is needed only if the project involves medical procedures and the
investigator is not a licensed physician.

03/30/01

Western Kentucky Univeristy
Bowling Green, KY

To Whom It May Concern:
The purpose of this letter is to let you know that Cathy Eden Ammerman has Sumner
Regional Medical Center's permission to conduct her study as outlined in her "Prevention
of Radiation-Induced Skin Reactions In Breast Cancer External Irradiation" proposal
dated December 11, 2000.

Sincerely,

Nicole Brashear
Vice President of Ancillary Services

Post Office Box 1558

555 Hartsville Pike

Gallatin, Tennessee

37066-1558

(615) 452-4210

SUMNER RADIATION ONCOLOGY CENTER
SUMNER REGIONAL HEALTH SYSTEMS
300 STEAM PLANT RD.
GALLATIN, TN. 37066

March 30, 2 0 01

RE:

RESEARCH PROJECT

To Whom I May Concern:
This letter is in support of the Cathy Amraerman proposed research project on
prevention of radiation induced dermatitis in breast cancer radiation. I am a
radiation oncologist at Sumner Regional Medical Center. I have had the
opportunity to work with Cathy when she filled in as our nurse during the
maternity leave for our usual nurse. I think this would be an excellent
research project and we would be glad to support Cathy in this endeavor.
If I can be of any further assistance, please feel free to call.
Sincerely yours,

Robert McClure, M.D.
Radiation Oncologist, Sumner Regional Medical Center
/wsj
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WESTERN KENTUCKY UNIVERSITY
Human Subjects Review Board
Office of Sponsored Programs
104 Foundation Building
270-745-4652; Fax 270-745-4211
E-mail: Phillip.Mvers@Wku.Edu
In future correspondence please refer to HS0195R, April 16, 2001
Cathy Eden Ammerman, RN
811 Harden Street
Gallatin, TN 37066
Dear Cathy:
Your research project, "Prevention of Radiation-Induced Dermatitis in Breast Cancer Irradiation," was reviewed by
the HSRB and it has been determined that risks to subjects are: (1) minimized and reasonable; and that (2) research
procedures are consistent with a sound research design and do not expose the subjects to unnecessary risk.
Reviewers determined that: (1) benefits to subjects are considered along with the importance of the topic and that
outcomes are reasonable; (2) selection of subjects is equitable; and (3) the purposes of the research and the research
setting is amenable to subjects' welfare and producing desired outcomes; that indications of coercion or prejudice are
absent, and that participation is clearly voluntary.
1.

In addition, the IRB found that: (1) written informed consent will be required of subjects. (2) Provision is made
for collecting, using and storing data in a manner that protects the safety and privacy of the subjects and the
confidentiality of the data. (3) Appropriate safeguards are included to protect the rights and welfare of the
subjects.
Your research therefore meets the criteria of Expedited Review and is approved.

2.

Please note that the institution is not responsible for any actions regarding this protocol before approval. If you
expand the project at a later date to use other instruments please re-apply. Copies of your request for human
subjects review, your application, and this approval, are maintained in the Office of Sponsored Programs at the
above address. Please report any changes to this approved protocol to this office. A Continuing Review
protocol will be sent to you in the future to determine the status of the project.

Director, OSP and
Human Protections Administrator
c:

Human Subjects File0195R
Dr. Beverly E. Holland, Department of Nursin:

HSApprovalAmmermanHS0195R

RECEIVED
FEB 2 2 2002
FOR HSRB USE ONLY:
Application Number:
HS0195
Date of Original IRB Approval:04/16/01
Level of Approval (please check one):
• Exempt
Was the project approved above or below minimum risk?:

~

Expedited
Below

O S P

Q Full Board
Q Above

(If "Above" HSRB Chair and one other HSRB reviewer may determine whether the PI needs to appear before the HSRB).

Name of Project:Prevention of Radiation-Induced Dermatitis in Breast Cancer Irradiation
Name of Researcher:Cathy Eden Ammerman
Department:Nursing
Is your data collection with human subjects complete?
0 Yes
Q No
(If "Yes", please sign below and return to the Office of Sponsored Programs, Room 106, Foundation Building. If
"No", please respond to the questions below, sign and return).
Thank you.
Continuing Review Checklist
1.

2.

3.

4.

5.

6.

Has there been any change in the level of risks to human subjects?
(If "Yes", please explain changes on a separate sheet).

Q

Yes Q

No

Have informed consent procedures changed so as to put subjects
above minimal risk? (If "Yes", please describe on a separate sheet).

Q

Yes Q

No

How many subjects have participated in the project in the past year?
Have any subjects withdrawn from the research due to adverse
events or any unanticipated problems? (If "Yes", please describe
on a separate sheet).

#

Q

Yes Q] No

Have there been any changes to the source(s) of subjects and the
Selection criteria? (If "Yes", please describe on a separate sheet).

Q] Yes Q

No

Have there been any changes to your research design that were not
specified in your application, including the frequency, duration and
location of each procedure. (If "Yes", please describe on a
separate sheet).

Q

Yes Q

No

Has there been any change to the way in which confidentiality of the
Data is maintained? (If "Yes", please describe on a separate sheet).

Q

Yes Q

No

..

Signature of Principal Investigator 1 O U ^ l b CKQ-xx-

^vals

r ^ c z ^ ^
Date

^
Date

Signature of Reviewer

"

Date

HSContinuingReviewFormRevisedO 1/22/02

SK/02/18/02

2

